SCHEMBL5118727

SCHEMBL5118727

O=C1CCc2cccc(NC(=O)CBr)c2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
LMNA P02545 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
THRB P10828 2/20 0.50
THRA P10827 1/20 0.50
KDM4E B2RXH2 3/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 3/20 0.40
CYP2C19 P33261 3/20 0.40
TSHR P16473 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
HPGD P15428 2/20 0.39
ATM Q13315 1/20 0.39
GAA P10253 1/20 0.39
CYP2A6 P11509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129173 0.82 ALDH1A1 (0.44) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL4005306 0.81 ALDH1A1 (0.71) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL13823608 0.81 CYP2A6 (0.46) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL8669256 0.81 NPC1 (0.57) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL1450722 0.75 TRPV1 (0.53) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL5128471 0.75 TRPV1 (0.53) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL287047 0.74 ALDH1A1 (0.41) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL14278349 0.74 NPC1 (0.53) ALDH1A1KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL24191934 0.73 CYP2A6 (0.47) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL4865203 0.72 ALDH1A1 (0.70) ALDH1A1LMNAMEN1KMT2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045546-A1 Tetradydro-Naphthalene And Urea Derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-21 US disclosed
US-20080045546-A1 Tetradydro-Naphthalene And Urea Derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-21 US disclosed
US-20080045546-A1 Tetradydro-Naphthalene And Urea Derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-21 US disclosed
EP-1678123-A1 TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES Bayer HealthCare AG (DE) 2006-07-12 EP disclosed
WO-2005040100-A1 TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045546-A1 Tetradydro-Naphthalene And Urea Derivatives NMUR1, GPR17, NMUR2 ALDH1A1 477/4885LMNA 3385/4885MEN1 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.